Last reviewed · How we verify
CD123 targeted CAR-NK cells
At a glance
| Generic name | CD123 targeted CAR-NK cells |
|---|---|
| Sponsor | Chongqing Precision Biotech Co., Ltd |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Off-the-shelf CD123 CAR-NK for R/R AML (EARLY_PHASE1)
- Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/refractory AML or BPDCN (PHASE1)
- Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm (PHASE1, PHASE2)
- Allogenic CD123-CAR-NK Cells in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CD123 targeted CAR-NK cells CI brief — competitive landscape report
- CD123 targeted CAR-NK cells updates RSS · CI watch RSS
- Chongqing Precision Biotech Co., Ltd portfolio CI